Predicting induction failure and outcome in those with ALL

File:Acute leukemia-ALL.jpg

When it comes to haematological malignancy, other than APML (where treatment has been revolutionised by ATRA and arsenic), outcomes are greatly variable. Studies looking at AML have found a great deal of chromosomal and genetic variations are responsible for prognostic heterogeneity – and now this article in the NEJM looks at the same for ALL. 

For haematology, this is a relatively massive study, looking at over 1,000 patients. High risk features included:

  • older age
  • high leucocyte count
  • leukaemia with a T cell phenotype
  • Philadelphia chromosome
  • 11q23 rearrangement

They also found that allo stem cell transplant was better than chemotherapy for T-cell, and the opposite for B-cell if there were no other adverse features. High hyperdiploidy and age between 1-5 was also favourable in those with precursor B-cell leukaemia.

It’s these articles that not only allow us to risk stratify, but also to target the therapies we do have (SCT, chemotherapy) more appropriately – at least until more specific therapies arrive.

Read it here.


source | NEJM

image | VashiDonsk


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s